Protein Kinase Cε Is a Predictive Biomarker of Aggressive Breast Cancer and a Validated Target for RNA Interference Anticancer Therapy
Open accessThe DOI matches its Crossref record.
Abstract
Tumor metastasis is the major cause of morbidity and mortality in patients with breast cancer. It is critical to identify metastasis enabling genes and understand how they are responsible for inducing specific aspects of the metastatic phenotype to allow for improved clinical detection and management. Protein kinase Cε (PKCε), a member of a family of serine/threonine protein kinases, is a transforming oncogene that has been reported to be involved in cell invasion and motility. In this study, we investigated the role of PKCε in breast cancer development and progression. High-density tissue microarray analysis showed that PKCε protein was detected in 73.6% (106 of 144) of primary tumors from invasive ductal breast cancer patients. Increasing PKCε staining intensity was associated with high histologic grade (P = 0.0206), positive Her2/neu receptor status (P = 0.0419), and negative estrogen (P = 0.0026) and progesterone receptor status (P = 0.0008). Kaplan-Meier analyses showed that PKCε was significantly associated with poorer disease-free and overall survival (log-rank, P = 0.0478 and P = 0.0414, respectively). RNA interference of PKCε in MDA-MB231 cells, an aggressive breast cancer cell line with elevated PKCε levels, resulted in a cell phenotype that was significantly less proliferative, invasive, and motile than the parental or the control RNA interference transfectants. Moreover, in vivo tumor growth of small interfering RNA-PKCε MDA-MB231 clones was retarded by a striking 87% (P < 0.05) and incidence of lung metastases was inhibited by 83% (P < 0.02). PKCε-deficient clones were found to have lower RhoC GTPase protein levels and activation. Taken together, these results revealed that PKCε plays a critical and causative role in promoting an aggressive metastatic breast cancer phenotype and as a target for anticancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Protein kinase C and other diacylglycerol effectors in cancer
Griner, E. M., & Kazanietz, M. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2110 · Cited by 978
Breast cancer diagnosis: Imaging techniques and biochemical markers
Jafari, S. H., Saadatpour, Z., Salmaninejad, A., Momeni, F., Mokhtari, M., Nahand, J. S., Rahmati, M., Mirzaei, H., & Kianmehr, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26379 · Cited by 410
Protein kinase C and cancer: what we know and what we do not
Garg, R., Benedetti, L. G., Abera, M. B., Wang, H., Abba, M., & Kazanietz, M. G. (2014) · Oncogene · doi:10.1038/onc.2013.524 · Cited by 303
Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression
Isakov, N. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.012 · Cited by 270
Protein kinase C isoforms: Multi-functional regulators of cell life and death
Reyland, M. (2009) · Frontiers in Bioscience · doi:10.2741/3385 · Cited by 266
Metadata
- Authors
- Pan, Q., Bao, L. W., Kleer, C. G., Sabel, M. S., Griffith, K. A., Teknos, T. N., & Merajver, S. D.
- Venue
- Cancer Research
- Published
- 2005-09-15
- Volume
- 65
- Issue
- 18
- Pages
- 8366-8371
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2131570311
- Cited by
- 145
- References
- 0
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protein Kinase Cε Is a Predictive Biomarker of Aggressive Breast Cancer and a Validated Target for RNA Interference Anticancer Therapy. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-0553
- The paper
- Pan, Q., Bao, L. W., Kleer, C. G., Sabel, M. S., Griffith, K. A., Teknos, T. N., & Merajver, S. D. (2005). Protein Kinase Cε Is a Predictive Biomarker of Aggressive Breast Cancer and a Validated Target for RNA Interference Anticancer Therapy. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-0553
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.